Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
暂无分享,去创建一个
J. Ambroso | H. Ellens | M. Reese | J. Bloomer | Liangfu Chen | S. Clarke | A. Harrell | Melanie Z. Sakatis | Melinda J. Reese | Andrew W. Harrell | Maxine A. Taylor | Ian A. Baines | Liangfu Chen | Jackie C. Bloomer | Eric Y. Yang | Harma M. Ellens | Jeffrey L. Ambroso | Cerys A. Lovatt | Andrew D. Ayrton | Stephen E. Clarke | C. Lovatt | Melanie Z Sakatis | A. Ayrton | Eric Yang | Maxine Taylor | Melanie Z Sakatis | Ian A Baines | Harma M Ellens | Jeffrey L Ambroso | Andrew D Ayrton | Ian Baines
[1] O. Pelkonen,et al. Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.
[2] G. Mulder,et al. A rapid, simple in vitro screening test, using [(3)H]glutathione and l-[(35)S]cysteine as trapping agents, to detect reactive intermediates of xenobiotics. , 1988, Toxicology in vitro : an international journal published in association with BIBRA.
[3] Yan Li,et al. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.
[4] A. Kalgutkar,et al. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. , 2007, Current drug metabolism.
[5] Kuresh Youdim,et al. Application of PBPK modelling in drug discovery and development at Pfizer , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[6] H. Masumoto,et al. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. , 2009, Drug metabolism and pharmacokinetics.
[7] Lisa M. Gangarosa,et al. Current Diagnosis and Treatment in Gastroenterology, 2nd edition , 2004 .
[8] Dominic P. Williams,et al. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. , 2008, Expert opinion on drug metabolism & toxicology.
[9] Chandan Saha,et al. Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.
[10] O. Chazouilleres,et al. [Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs]. , 2000, Gastroenterologie clinique et biologique.
[11] A. Kalgutkar,et al. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. , 2009, Chemical research in toxicology.
[12] Masashi Yabuki,et al. Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver Proteins , 2009, Drug Metabolism and Disposition.
[13] P. Dansette,et al. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. , 2005, Current drug metabolism.
[14] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[15] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[16] Jinping Gan,et al. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. , 2005, Chemical research in toxicology.
[17] W. Humphreys,et al. In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation. , 2009, Chemical research in toxicology.
[18] Carole E Shardlow,et al. Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk , 2011, Drug Metabolism and Disposition.
[19] B. Faller,et al. CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs , 2011, Drug Metabolism and Disposition.
[20] J. Uetrecht. Idiosyncratic drug reactions: past, present, and future. , 2008, Chemical research in toxicology.
[21] Nurgun Oktik. THE DEVELOPMENT OF HIGHER , 2006 .
[22] A. Stepan,et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.
[23] F. Ballet,et al. Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.
[24] J. Boyd,et al. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. , 2004, Journal of pharmaceutical and biomedical analysis.
[25] Kazuhito Shiosakai,et al. Combination of glutathione trapping and time-dependent inhibition assays as a predictive method drugs generating highly reactive metabolites , 2011 .
[26] T. Baillie,et al. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. , 2004, Chemical research in toxicology.
[27] Osamu Okazaki,et al. Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide , 2010, Drug Metabolism and Disposition.
[28] Tze Chieh Shiao,et al. Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. , 2010, Rapid communications in mass spectrometry : RCM.
[29] R Scott Obach,et al. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. , 2008, Chemical research in toxicology.
[30] P. Jeffrey,et al. Approaches to assessing drug safety in the discovery phase , 2010 .
[31] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[32] Ian D. Wilson,et al. Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.
[33] Jeffrey Ambroso,et al. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. , 2011, Chemico-biological interactions.
[34] Y. Masubuchi,et al. Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs , 2007, Critical reviews in toxicology.
[35] Osamu Okazaki,et al. A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding , 2009, Drug Metabolism and Disposition.